Literature DB >> 23971882

Faecalibacterium prausnitzii supernatant improves intestinal barrier function in mice DSS colitis.

Anders H Carlsson1, Olena Yakymenko, Isabelle Olivier, Fathima Håkansson, Emily Postma, Asa V Keita, Johan D Söderholm.   

Abstract

OBJECTIVE. The intestinal microbiota plays a substantial role in the pathogenesis of inflammatory bowel disease (IBD). Faecalibacterium prausnitzii (FP) is underrepresented in IBD patients and have been suggested to have anti-inflammatory effects in mice. Increased intestinal permeability is common in IBD but the relationship between FP and intestinal barrier function has not been investigated. Our aim was to study treatment with FP supernatant on intestinal barrier function in a dextran sodium sulfate (DSS) colitis mice model. MATERIAL AND METHODS. C57BL/6 mice received 3% DSS in tap water ad libitum during five days to induce colitis. From day 3 the mice received a daily gavage with FP supernatant or broth during seven days. Ileum and colon were mounted in Ussing chambers for permeability studies with (51)Cr-EDTA and Escherichia coli K-12. Colon was saved for Western blot analyses of tight junction proteins. RESULTS. DSS-treated mice showed significant weight loss and colon shortening. Gavage with FP supernatant resulted in a quicker recovery after DSS treatment and less extensive colonic shortening. Ileal mucosa of DSS mice showed a significant increase in (51)Cr-EDTA-passage compared to controls. (51)Cr-EDTA passage was significantly decreased in mice receiving FP supernatant. No significant differences were observed in passage of E. coli K12. Western blots showed a trend to increased claudin-1 and claudin-2 expressions in DSS mice. CONCLUSIONS. Supernatant of FP enhances the intestinal barrier function by affecting paracellular permeability, and may thereby attenuate the severity of DSS-induced colitis in mice. These findings suggest a potential role of FP in the treatment of IBD.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23971882     DOI: 10.3109/00365521.2013.828773

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  62 in total

1.  Mucosa-associated Faecalibacterium prausnitzii phylotype richness is reduced in patients with inflammatory bowel disease.

Authors:  Mireia Lopez-Siles; Margarita Martinez-Medina; Carles Abellà; David Busquets; Miriam Sabat-Mir; Sylvia H Duncan; Xavier Aldeguer; Harry J Flint; L Jesús Garcia-Gil
Journal:  Appl Environ Microbiol       Date:  2015-08-21       Impact factor: 4.792

2.  Lactobacillus fermentum species ameliorate dextran sulfate sodium-induced colitis by regulating the immune response and altering gut microbiota.

Authors:  You Jin Jang; Woon-Ki Kim; Dae Hee Han; Kiuk Lee; Gwangpyo Ko
Journal:  Gut Microbes       Date:  2019-04-03

Review 3.  Faecalibacterium prausnitzii: from microbiology to diagnostics and prognostics.

Authors:  Mireia Lopez-Siles; Sylvia H Duncan; L Jesús Garcia-Gil; Margarita Martinez-Medina
Journal:  ISME J       Date:  2017-01-03       Impact factor: 10.302

4.  Characterization of gut microbiota composition in HIV-infected patients with metabolic syndrome.

Authors:  María Jesús Villanueva-Millán; Patricia Pérez-Matute; Emma Recio-Fernández; José-Miguel Lezana Rosales; José-Antonio Oteo
Journal:  J Physiol Biochem       Date:  2019-03-28       Impact factor: 4.158

5.  Colonic Lesions, Cytokine Profiles, and Gut Microbiota in Plasminogen-Deficient Mice.

Authors:  Bill Vestergaard; Łukasz Krych; Leif R Lund; Bettina P Jørgensen; Lars Hansen; Henrik E Jensen; Dennis S Nielsen; Axel K Hansen
Journal:  Comp Med       Date:  2015-10       Impact factor: 0.982

Review 6.  Novel perspectives on therapeutic modulation of the gut microbiota.

Authors:  Justin L McCarville; Alberto Caminero; Elena F Verdu
Journal:  Therap Adv Gastroenterol       Date:  2016-04-04       Impact factor: 4.409

7.  Changes in Weight Status and the Intestinal Microbiota Among College Freshman, Aged 18 Years.

Authors:  Elizabeth K Journey; Carmen P Ortega-Santos; Meg Bruening; Corrie M Whisner
Journal:  J Adolesc Health       Date:  2019-08-30       Impact factor: 5.012

8.  Emu Oil Improves Clinical Indicators of Disease in a Mouse Model of Colitis-Associated Colorectal Cancer.

Authors:  Lauren C Chartier; Gordon S Howarth; Ian C Lawrance; Debbie Trinder; Scott J Barker; Suzanne Mashtoub
Journal:  Dig Dis Sci       Date:  2017-12-06       Impact factor: 3.199

Review 9.  Innate and adaptive immune responses in Parkinson's disease.

Authors:  Aubrey M Schonhoff; Gregory P Williams; Zachary D Wallen; David G Standaert; Ashley S Harms
Journal:  Prog Brain Res       Date:  2019-12-05       Impact factor: 2.453

10.  Fungal Dysbiosis in Mucosa-associated Microbiota of Crohn's Disease Patients.

Authors:  Giuseppina Liguori; Bruno Lamas; Mathias L Richard; Giovanni Brandi; Gregory da Costa; Thomas W Hoffmann; Massimo Pierluigi Di Simone; Carlo Calabrese; Gilberto Poggioli; Philippe Langella; Massimo Campieri; Harry Sokol
Journal:  J Crohns Colitis       Date:  2015-11-15       Impact factor: 9.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.